Liquidia (NASDAQ:LQDA) Coverage Initiated by Analysts at Raymond James

Raymond James started coverage on shares of Liquidia (NASDAQ:LQDA) in a report issued on Friday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $27.00 price objective on the stock.

A number of other analysts also recently issued reports on LQDA. Oppenheimer started coverage on Liquidia in a research note on Tuesday, June 25th. They issued a market perform rating on the stock. HC Wainwright restated a buy rating and issued a $32.00 price target on shares of Liquidia in a research report on Wednesday, July 10th. Finally, Needham & Company LLC lowered their price objective on shares of Liquidia from $28.00 to $25.00 and set a buy rating for the company in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Liquidia currently has a consensus rating of Moderate Buy and an average target price of $22.00.

Liquidia Trading Up 2.0 %

Shares of LQDA stock opened at $14.11 on Friday. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -9.04 and a beta of 0.32. Liquidia has a 12-month low of $5.71 and a 12-month high of $16.99. The stock’s 50-day moving average price is $12.23 and its 200-day moving average price is $13.35.

Insiders Place Their Bets

In other news, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $48,942.18. Following the transaction, the chief financial officer now directly owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the transaction, the chief financial officer now owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the sale, the chief executive officer now owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The disclosure for this sale can be found here. Insiders sold 21,437 shares of company stock valued at $268,549 over the last three months. 31.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC purchased a new stake in Liquidia during the second quarter valued at approximately $27,000. Hilltop National Bank acquired a new stake in shares of Liquidia in the 2nd quarter worth $33,000. Deuterium Capital Management LLC purchased a new stake in Liquidia in the second quarter valued at about $120,000. DMC Group LLC purchased a new stake in shares of Liquidia during the second quarter worth about $122,000. Finally, Whitcomb & Hess Inc. purchased a new position in shares of Liquidia in the 2nd quarter valued at approximately $126,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).